Tyrosine-protein kinase 6 (PTK6)

Tyrosine-protein kinase 6 (PTK6), also known as breast tumor kinase (BRK), is an intracellular non-receptor tyrosine protein kinase encoded by the *PTK6* gene on chromosome 20q13.33. It primarily functions within epithelial tissues where it regulates signal transduction pathways involved in cellular differentiation, proliferation, migration, and survival. While normally expressed at low levels in differentiated cells lining gastrointestinal tract and skin epithelium, aberrant overexpression or activation has been observed in several human cancers—including breast and prostate—where it contributes to malignant transformation by promoting growth factor sensitivity, resistance to anoikis/apoptosis via AKT activation/phosphorylation cascades,[9] enhanced motility/metastasis through focal adhesion interactions,[8] and modulation of EMT processes. Both catalytic-dependent activities (phosphorylating substrates) and scaffolding/adaptor roles independent of enzymatic function have been described. Targeting PTK6 remains an area of active research; while small-molecule ATP-site inhibitors can reduce some aspects of tumorigenesis experimentally,[4] their clinical utility requires further validation given complex biology. Commonly used aliases include BRK ("breast tumor kinase") alongside its gene/protein symbol "PTK6."[1][2][7]

Other names

Breast tumor kinase (BRK)PTK6Protein-tyrosine kinase 6

Drugs targeting this molecule generally act as ATP-site competitive inhibitors that block the catalytic activity of the enzyme, thereby interfering with downstream phosphorylation events critical for oncogenic signaling pathways. However, both kinase-dependent and independent functions have been described; thus inhibition may not always translate into anti-tumor efficacy depending on context.[4]